0001209191-20-039086.txt : 20200626 0001209191-20-039086.hdr.sgml : 20200626 20200626163325 ACCESSION NUMBER: 0001209191-20-039086 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200624 FILED AS OF DATE: 20200626 DATE AS OF CHANGE: 20200626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klein Lawrence Otto CENTRAL INDEX KEY: 0001762583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 20994526 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 610 MAIN STREET 7TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-24 0 0001674416 CRISPR Therapeutics AG CRSP 0001762583 Klein Lawrence Otto C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 CBO & COO Common Shares 2020-06-24 4 M 0 38666 5.86 A 58666 D Common Shares 2020-06-24 4 S 0 15966 75.9279 D 42700 D Common Shares 2020-06-24 4 S 0 22700 76.5011 D 20000 D Common Shares 2020-06-24 4 M 0 26422 12.57 A 46422 D Common Shares 2020-06-24 4 S 0 6600 74.8974 D 39822 D Common Shares 2020-06-24 4 S 0 3934 75.937 D 35888 D Common Shares 2020-06-24 4 S 0 800 76.5012 D 35088 D Common Shares 2020-06-24 4 S 0 12175 75.3227 D 22913 D Common Shares 2020-06-24 4 S 0 2913 76.2575 D 20000 D Common Shares 2020-06-25 4 M 0 4912 12.57 A 24912 D Common Shares 2020-06-25 4 S 0 4912 75.1776 D 20000 D Stock Option (Right to Buy) 5.86 2020-06-24 4 M 0 38666 0.00 D 2026-03-01 Common Shares 38666 0 D Stock Option (Right to Buy) 12.57 2020-06-24 4 M 0 26422 0.00 D 2026-07-14 Common Shares 26422 13578 D Stock Option (Right to Buy) 12.57 2020-06-25 4 M 0 4912 0.00 D 2026-07-14 Common Shares 4912 8666 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.32 to $76.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.32 to $76.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.40 to $75.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.40 to $76.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.45 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.03 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.6850, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 43,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016. /s/ Michael Esposito, attorney-in-fact 2020-06-26